Skip to content

Medical emergency? What to do

UK Alzheimer's drug fight goes before appeal court

3-RXPublished April 14, 20081 min read

Key points

  • A test case legal battle over funding for Alzheimer's drugs in Britain went before the Court of Appeal on Monday, pitching Japan's Eisai Co Ltd against the healthcare cost effectiveness watchdog NICE.
  • The hearing is scheduled to last two days, after which the appeal court is expected to give its decision in writing at a later date.
  • Drugmakers and patient groups took legal action to try to prove NICE's decision-making was flawed, but the High Court in London upheld its restrictions on use of the drugs, which cost around $5 a day.
  • Eisai and its marketing partner Pfizer Inc are contesting curbs imposed by the National Institute for Health and Clinical Excellence (NICE) on the use of Alzheimer's drugs within the state-run National Health Service.

A test case legal battle over funding for Alzheimer's drugs in Britain went before the Court of Appeal on Monday, pitching Japan's Eisai Co Ltd against the healthcare cost effectiveness watchdog NICE.

Eisai and its marketing partner Pfizer Inc are contesting curbs imposed by the National Institute for Health and Clinical Excellence (NICE) on the use of Alzheimer's drugs within the state-run National Health Service.

The hearing is scheduled to last two days, after which the appeal court is expected to give its decision in writing at a later date.

The two drugmakers, which co-promote the market-leading treatment Aricept, lost an earlier High Court fight last August. They are trying to overturn a NICE ruling that drugs like Aricept should not be paid for by the state health service for treating the early stages of Alzheimer's disease.

Drugmakers and patient groups took legal action to try to prove NICE's decision-making was flawed, but the High Court in London upheld its restrictions on use of the drugs, which cost around $5 a day.

Anti-cholinesterase drugs such as Aricept can help but not cure some Alzheimer's patients. Other products affected by NICE's decision include Exelon from Novartis AG, Ebixa from Lundbeck A/S and Reminyl from Shire Plc, which is sold elsewhere by Johnson & Johnson as Razadyne.

LONDON (Reuters)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underNeurology

Keep reading

Brain

Research Explores Little-Understood Brain Disease

The population of aged persons worldwide is expanding rapidly, and it is becoming increasingly clear that there are many different diseases that affect the minds of these individuals. Researchers at the University of…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.